{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:52:04Z","timestamp":1792525924848,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-26584-y","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T09:37:31Z","timestamp":1764322651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["In vitro drug susceptibility of Leishmania donovani from visceral leishmaniasis patients with and without HIV coinfection in Northwestern Ethiopia"],"prefix":"10.1038","volume":"15","author":[{"given":"Sultan","family":"Tufa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markos","family":"Tadele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helina","family":"Fikre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Melkamu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arega","family":"Yeshanew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Atnafu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zemenay","family":"Mulugeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagaga","family":"Kenea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birtukan","family":"Kebede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asrat","family":"Hailu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"26584_CR1","doi-asserted-by":"publisher","unstructured":"Adriaensen, W. et al. Immunomodulatory therapy of visceral leishmaniasis in human immunodeficiency virus-coinfected patients. Front. Immunol. 8, 1943. https:\/\/doi.org\/10.3389\/fimmu.2017.01943 (2018).","DOI":"10.3389\/fimmu.2017.01943"},{"issue":"5","key":"26584_CR2","doi-asserted-by":"publisher","first-page":"e0006527","DOI":"10.1371\/journal.pntd.0006527","volume":"12","author":"C Abongomera","year":"2018","unstructured":"Abongomera, C. et al. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in ethiopia: A retrospective cohort study. PLoS Negl. Trop. Dis. 12(5), e0006527. https:\/\/doi.org\/10.1371\/journal.pntd.0006527 (2018).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"26584_CR3","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1007\/s40265-013-0133-0","volume":"73","author":"B Monge-Maillo","year":"2013","unstructured":"Monge-Maillo, B. & Lo\u00b4pez-Ve\u00b4lez, R. Therapeutic options for visceral leishmaniasis. Drugs 73, 1863\u20131888. https:\/\/doi.org\/10.1007\/s40265-013-0133-0 (2013).","journal-title":"Drugs"},{"key":"26584_CR4","doi-asserted-by":"publisher","unstructured":"Aruleba, R. T., Carter, K. C., Brombacher, F. & Hurdayal, R. Frank brombacher and Ramona Hurdayal. Can we Harness immune responses to improve drug treatment in leishmaniasis? Microorganisms 8, 1069. https:\/\/doi.org\/10.3390\/microorganisms8071069 (2020).","DOI":"10.3390\/microorganisms8071069"},{"issue":"11","key":"26584_CR5","doi-asserted-by":"publisher","first-page":"e889","DOI":"10.1371\/journal.pntd.0000889","volume":"4","author":"T Gelanew","year":"2010","unstructured":"Gelanew, T. et al. Inference of population structure of Leishmania donovani strains isolated from different Ethiopian visceral leishmaniasis endemic areas. PLoS Negl. Trop. Dis. 4(11), e889 (2010).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"26584_CR6","doi-asserted-by":"publisher","first-page":"e00048","DOI":"10.1128\/CMR.00048-18","volume":"31","author":"F Alves","year":"2018","unstructured":"Alves, F. et al. Recent development of visceral leishmaniasis treatments: Successes, pitfalls, and perspectives. Clin. Microbiol. Rev. 31, e00048\u2013e00018. https:\/\/doi.org\/10.1128\/CMR.00048-18 (2018).","journal-title":"Clin. Microbiol. Rev."},{"key":"26584_CR7","doi-asserted-by":"publisher","unstructured":"Joseph, N. et al. Lockwood Clinical aspects of visceral leishmaniasis in HIV infection. Curr. Opin. Infect. Dis. 26, 1\u20139. https:\/\/doi.org\/10.1097\/QCO.0b013e32835c2198 (2013).","DOI":"10.1097\/QCO.0b013e32835c2198"},{"key":"26584_CR8","doi-asserted-by":"publisher","unstructured":"Lindoso, J., Moreira, C., Cunha, M. A., Queiroz, I. T. & Auckland, N. Z. Visceral leishmaniasis and HIV coinfection: Current perspectives. HIV\/AIDS 10, 193\u2013201. https:\/\/doi.org\/10.2147\/HIV.S143929 (2018)","DOI":"10.2147\/HIV.S143929"},{"key":"26584_CR9","doi-asserted-by":"crossref","unstructured":"Maes, L., Cos, P. & Croft, S. The relevance of susceptibility tests, breakpoints and markers. in Drug Resistance in Leishmania Parasites  (eds Ponte-Sucre, A., Diaz, E. & Padr\u00f3n-Nieves, M.) 407\u2013429 (Springer Vienna, 2013).","DOI":"10.1007\/978-3-7091-1125-3_19"},{"key":"26584_CR10","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1128\/AAC.00548-09","volume":"53","author":"M Vermeersch","year":"2009","unstructured":"Vermeersch, M. et al. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: Practical relevance of stage-specific differences. Antimicrob. Agents Chemother. 53, 3855\u20133859 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"26584_CR11","doi-asserted-by":"crossref","unstructured":"Seifert, K., Escobar, P. & Croft, S. L. In vitro activity of anti leishmanial drugs against Leishmania donovani is host cell dependent. J. Antimicrob. Chemother. 65, 508\u2013511 (2010).","DOI":"10.1093\/jac\/dkp500"},{"key":"26584_CR12","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.3390\/molecules25112551","volume":"25","author":"M Laura","year":"2020","unstructured":"Laura, M. et al.  A multi-species phenotypic screening assay for leishmaniasis drug discovery shows that active compounds display a high degree of species-specificity. Molecules 25, 2551. https:\/\/doi.org\/10.3390\/molecules25112551 (2020).","journal-title":"Molecules"},{"key":"26584_CR13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0924-8579(03)00125-0","volume":"22","author":"K Seifert","year":"2003","unstructured":"Seifert, K. et al. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int. J. Antimicrob. Agents. 22, 380\u2013387 (2003).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"26584_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.molbiopara.2008.12.007","volume":"164","author":"A Jhingran","year":"2009","unstructured":"Jhingran, A., Chawla, B., Saxena, S., Barrett, M. P. & Madhubala, R. Paromomycin: Uptake and resistance in Leishmania donovani. Molec Bioch Para. 164(2), 111\u2013117 (2009).","journal-title":"Molec Bioch Para."},{"issue":"4","key":"26584_CR15","doi-asserted-by":"publisher","first-page":"e0196247","DOI":"10.1371\/journal.pone.0196247","volume":"13","author":"C Franco-Mu\u00f1oz","year":"2018","unstructured":"Franco-Mu\u00f1oz, C., Manjarre\u00c2s-Estremor, M. & Ovalle-Bracho, C. Intraspecies differences in natural susceptibility to amphotericine B of clinical isolates of Leishmania subgenus Viannia. PLoS ONE. 13 (4), e0196247. https:\/\/doi.org\/10.1371\/journal.pone.0196247 (2018).","journal-title":"PLoS ONE"},{"key":"26584_CR16","doi-asserted-by":"publisher","unstructured":"Di Giorgio, C. et al. Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis. J. Antimicrob. Chemother. 44, 716. (1999). https:\/\/doi.org\/10.1093\/jac\/44.1.71 PMID: 10459812.","DOI":"10.1093\/jac\/44.1.71"},{"issue":"6","key":"26584_CR17","doi-asserted-by":"publisher","first-page":"e0005641","DOI":"10.1371\/journal.pntd.0005641","volume":"11","author":"DK Deep","year":"2017","unstructured":"Deep, D. K. et al. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress. PLoS Negl. Trop. Dis. 11(6), e0005641. https:\/\/doi.org\/10.1371\/journal.pntd.0005641 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"26584_CR18","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1086\/595710","volume":"15","author":"L Lachaud","year":"2009","unstructured":"Lachaud, L. et al. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients co-infected with HIV type 1 and Leishmania infantum. Clin. Infec Dis. 15, e16\u2013e22 (2009).","journal-title":"Clin. Infec Dis."},{"key":"26584_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4269\/ajtmh.2001.64.187","volume":"64","author":"R Palacios","year":"2001","unstructured":"Palacios, R., Osorio, L. E., Grajalew, L. F. & Ochoa, M. T. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania Viannia species. Am. J. Trop. Med. Hyg. 64, 187\u2013193 (2001).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"26584_CR20","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1046\/j.1365-3156.2001.00795.x","volume":"6","author":"A Bryceson","year":"2001","unstructured":"Bryceson, A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop. Med. Int. Health  6, 928\u2013934 (2001).","journal-title":"Trop. Med. Int. Health"},{"key":"26584_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4269\/ajtmh.2005.72.421","volume":"72","author":"J Soto","year":"2005","unstructured":"Soto, J., Toledo, J., Vega, J. & Berman, J. Short report: Efficacy of pentavalent antimony for treatment of Colombian cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 72, 421\u2013422 (2005).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"26584_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/0169-4758(91)90079-4","volume":"7","author":"MJ Doenhoff","year":"1991","unstructured":"Doenhoff, M. J., Modha, J., Lambertucci, J. R. & McLaren, D. J. The immune dependence of chemotherapy. Parasitol. Today 7, 16\u201318 (1991).","journal-title":"Parasitol. Today"},{"issue":"1","key":"26584_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/00005792-200101000-00006","volume":"80","author":"V Pintado","year":"2001","unstructured":"Pintado, V., Martin-Rabadan, P., Rivera, M. L., Moreno, S. & Bouza, E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltim). 80(1), 54\u201373 (2001).","journal-title":"Medicine (Baltim)."},{"key":"26584_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4103\/0022-3859.929","volume":"49","author":"R Paredes","year":"2003","unstructured":"Paredes, R. et al. Leishmaniasis in HIV infection. J. Postgrad. Med. 49, 39\u201349 (2003).","journal-title":"J. Postgrad. Med."},{"key":"26584_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1128\/CMR.00061-07","volume":"21","author":"J Alvar","year":"2008","unstructured":"Alvar, J. et al. The relationship between leishmaniasis and AIDS: The second 10 years. ClinMicrobiol Rev. 21, 334\u2013359. https:\/\/doi.org\/10.1128\/CMR.00061-07 (2008).","journal-title":"ClinMicrobiol Rev."},{"key":"26584_CR26","doi-asserted-by":"crossref","unstructured":"Gebreyohannes, E. A., Bhagvathula, A. S., Abegaz, T. M. & Seid, M. A.  Tadesse Melaku Abegaz and Mohammed Assen Seid. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: A systematic review and meta-analysis. Infec Dis. Pov. 7, 108 (2018).","DOI":"10.1186\/s40249-018-0491-7"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26584-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26584-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26584-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T22:01:09Z","timestamp":1764712869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26584-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["26584"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-26584-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"18 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were carried out in accordance with ARRIVE guidelines (\n                      \n                      ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"42588"}}